Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.
about
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierMolecular mechanism of a novel CD59-binding peptide sp22 induced tumor cells apoptosis.Drug delivery by red blood cells: vascular carriers designed by mother nature.Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis.
P2860
Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Enhanced complement susceptibi ...... and decay accelerating factor.
@en
type
label
Enhanced complement susceptibi ...... and decay accelerating factor.
@en
prefLabel
Enhanced complement susceptibi ...... and decay accelerating factor.
@en
P2093
P2860
P356
P1433
P1476
Enhanced complement susceptibi ...... and decay accelerating factor
@en
P2093
A B Zaltzman
C W Van den Berg
V R Muzykantov
P2860
P304
P356
10.1042/BJ3070651
P407
P478
307 ( Pt 3)
P50
P577
1995-05-01T00:00:00Z